FDA Approves AbbVie’s Duopa For Treating Advanced Parkinson’s Disease

AbbVie Inc. Jan. 12 said the Food and Drug Administration has approved Duopa (carbidopa and levodopa) enteral suspension for treating motor fluctuations for people with advanced Parkinson’s disease.

Duopa is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a tube, the North Chicago, Ill.-based company said. It was approved by the FDA as an orphan drug, a designation granted to products intended for treating rare diseases or conditions affecting fewer than 200,000 patients in the U.S.

“The FDA approval of Duopa is another significant milestone for ...